Clinical Trial Update: Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating low-dose plerixafor plus G-CSF to mobilize stem cells for autologous peripheral blood transplantation in lymphoma and multiple mye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• Filgrastim (filgrastim)
• Plerixafor (Plerixafor)

Snippet

Sponsor: Hospital Universitario Dr. Jose E. Gonzalez | Conditions: Lymphoma, Non-Hodgkin, Lymphoma, Hodgkin | Phase 2 | Status: UNKNOWN